Development and validation of a prognostic model incorporating tumor thrombus grading for nonmetastatic clear cell renal cell carcinoma with tumor thrombus: A multicohort study
单位：[1]Department of Urology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China[2]Department of Urology, Jinling Hospital, Jinling School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China[3]Department of Pathology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China[4]Department of Health Statistics, Naval Medical University, Shanghai, China[5]Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China[6]Department of Urology, Qilu Hospital of Shandong University, Jinan, Shandong, China[7]Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland[8]Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, Shanghai, China[9]Department of Pathology, Changhai Hospital,NavalMedical University, Shanghai, China[10]Department of Urology, Daping Hospital, Army Medical University, Chongqing, China[11]Department of Pathology, Qilu Hospital of Shandong University, Jinan, Shandong, China[12]Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei,China外科学系华中科技大学同济医学院附属同济医院泌尿外科[13]Department of Pathology, Drum Tower Hospital, Clinical School of Medical College, Nanjing University, Nanjing, Jiangsu, China[14]Department of Urology, Drum Tower Hospital, Clinical School of Medical College, Nanjing University, Nanjing, Jiangsu, China[15]Department of Pathology, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China[16]Department of Urology, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China[17]Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China[18]Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China浙江大学医学院附属第一医院[19]Department of Urology, Huashan Hospital, Fudan University, Shanghai, China[20]Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China[21]Department of Pathology, Affiliated Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China[22]Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China[23]Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China[24]Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China[25]Department of Urology, Urology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China[26]Department of Urology, Anhui Provincial Hospital, The First Hospital of the University of Science and Technology of China, Hefei, Anhui, China[27]Department of Urology, Shanghai East Hospital, Tongji University, Shanghai, China[28]Department of Pathology, Shanghai East Hospital, Tongji University, Shanghai, China[29]Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shanxi, China[30]Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shanxi, China[31]Department of Medical Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China[32]Clinic of General, Oncological and Functional Urology, Medical University of Warsaw,Warsaw, Poland
National Natural Science Foundation of
China, Grant/Award Numbers: 81772740,
82173345, 81972333, 81730073, 81872074;
Natural Science Foundation of Jiangsu
Province, Grant/Award Number:
BK20200006; China National Key
Research and Development Program Stem
Cell and Translational Research Key
Projects, Grant/Award Number:
2018YFA0108300; Jiangsu Province for
Distinguished Postdoctor, Grant/Award
Number: 2022ZB741
第一作者单位：[1]Department of Urology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China[2]Department of Urology, Jinling Hospital, Jinling School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China[*1]Department of Urology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, 305 East Zhongshan Road, Nanjing 210000, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Urology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China[2]Department of Urology, Jinling Hospital, Jinling School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China[5]Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China[*1]Department of Urology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, 305 East Zhongshan Road, Nanjing 210000, China[*2]Department of Urology, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai 200433, China
推荐引用方式(GB/T 7714)：
Qu Le,Chen Hui,Chen Qi,et al.Development and validation of a prognostic model incorporating tumor thrombus grading for nonmetastatic clear cell renal cell carcinoma with tumor thrombus: A multicohort study[J].MEDCOMM.2023,4(4):doi:10.1002/mco2.300.
APA：
Qu Le,Chen Hui,Chen Qi,Ge Silun,Jiang Aimin...&Wang Linhui.(2023).Development and validation of a prognostic model incorporating tumor thrombus grading for nonmetastatic clear cell renal cell carcinoma with tumor thrombus: A multicohort study.MEDCOMM,4,(4)
MLA：
Qu Le,et al."Development and validation of a prognostic model incorporating tumor thrombus grading for nonmetastatic clear cell renal cell carcinoma with tumor thrombus: A multicohort study".MEDCOMM 4..4(2023)
医学